A revolutionary targeted killer T-Cell immune system therapy (immunotherapy) platform validated by extensive animal testing in mice and macaques.
Medicines that precisely treat cancer and viral disease with minimal side effects.
Stable Dry Powder
Multiple Delivery Pathways
For Virus – inhalation, intramuscular
For Cancer – intranodal, intramuscular
Quick disease-specific therapy creation. Rapid high-volume production capability.
The Peer Reviewed Journal Vaccines Published the Results of Flow Pharma’s COVID-19 Primate Study
Company Update, COVID-19, FLOVID-20
Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax™ peptide vaccine platform technology, today announced the publication of an article describing research performed at the University of Texas Medical Branch at Galveston (UTMB)
Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies
In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China.